Introduction

Synthetic cannabinoids continue to evolve rapidly, with ADB-BUTINACA appearing in drug seizure reports across both the United States and Europe.

Market Trends

Authorities such as:

• U.S. forensic laboratories
• European drug monitoring agencies

have identified ADB-BUTINACA alongside:

• ADB-BINACA
• ADMB-BINACA
• MDMB-BINACA

Why These Compounds Spread

Key factors include:

• ease of chemical modification
• high potency at low doses
• challenges in regulation

Public Health Impact

Hospitals and emergency systems in both regions have reported:

• increased intoxication cases
• severe neurological symptoms
• unknown mixtures of synthetic cannabinoids

Conclusion

ADB-BUTINACA represents the ongoing challenge of controlling rapidly evolving synthetic drug markets.